Department of Gastroenterology, Tochigi Cancer Center, Tochigi, Japan.
Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Dig Endosc. 2022 Jul;34(5):1042-1051. doi: 10.1111/den.14223. Epub 2022 Feb 7.
Endoscopic mucosal resection (EMR) is the gold standard for the treatment of noninvasive large colorectal lesions, despite challenges associated with nonlifting lesions and a high rate of local recurrence. Endoscopic submucosal dissection (ESD) offers the possibility of overcoming these EMR limitations. However, a higher risk of complications and longer procedure time prevented its dissemination. As ESD now provides more stable results because of standardized techniques compared with those used earlier, this study aimed to quantify the rates of en bloc and curative resections, as well as ESD complications, in the present situation.
A multicenter, large-scale, prospective cohort trial of ESD was conducted at 20 institutions in Japan. Consecutive patients scheduled for ESD were enrolled from February 2013 to January 2015.
ESD was performed for 1883 patients (1965 lesions). The mean procedure time was 80.6 min; en bloc and curative resections were achieved in 1759 (97.0%) and 1640 (90.4%) lesions, respectively, in epithelial lesions ≥20 mm. Intra- and postprocedural perforations occurred in 51 (2.6%) and 12 (0.6%) lesions, respectively, and emergency surgery for adverse events was performed in nine patients (0.5%).
This trial conducted after the standardization of the ESD technique throughout Japan revealed a higher curability, shorter procedure time, and lower risk of complications than those reported previously. Considering that the target lesions of ESD are more advanced than those of EMR, ESD can be a first-line treatment for large colorectal lesions with acceptable risk and procedure time. (Clinical Trial Registration: UMIN000010136).
内镜黏膜切除术(EMR)是治疗非侵袭性大肠黏膜病变的金标准,但存在病变抬举不良和局部复发率高的问题。内镜黏膜下剥离术(ESD)为克服这些 EMR 局限性提供了可能。然而,由于并发症风险较高和手术时间较长,ESD 并未得到广泛应用。由于与早期使用的技术相比,ESD 现在采用了标准化技术,因此能提供更稳定的结果。本研究旨在评估目前情况下整块切除和治愈性切除的比例以及 ESD 并发症的发生率。
在日本 20 家机构开展了一项多中心、大规模、前瞻性 ESD 队列研究。于 2013 年 2 月至 2015 年 1 月连续纳入拟行 ESD 的患者。
共对 1883 例(1965 处病变)患者进行了 ESD 治疗。平均手术时间为 80.6 分钟;上皮病变≥20 mm 的患者中,1759 例(97.0%)和 1640 例(90.4%)病变实现了整块切除和治愈性切除。术中及术后穿孔分别发生于 51 处(2.6%)和 12 处(0.6%)病变,9 例(0.5%)患者因不良事件行急诊手术。
本研究在日本范围内规范 ESD 技术后开展,结果显示 ESD 的治愈率更高、手术时间更短、并发症风险更低,优于既往报道。鉴于 ESD 的治疗目标病变比 EMR 更严重,ESD 可作为具有可接受风险和手术时间的大肠黏膜病变的一线治疗方法。(临床试验注册:UMIN000010136)。